Acute Coronary Syndromes Clinical Trial
— EPICOROfficial title:
EPICOR Asia-China Extension. Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension
Verified date | September 2018 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is to describe the long-term antithrombotic management patterns in a real-life setting for patients hospitalized with an acute coronary syndrome in China.
Status | Completed |
Enrollment | 2334 |
Est. completion date | April 5, 2017 |
Est. primary completion date | April 5, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Written informed consent has been provided. 2. Contact Order Form has been provided 3. Aged 18 years or older. 4. Enrolled in EPICOR Asia study and completed the 2 year follow-up. Exclusion Criteria: 1. Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances, alcohol or drug abuse). 2. Already included in the EPICOR Asia-China Extension observational study. 3. Presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy. 4. Current participation in an interventional clinical trial. 5. Patients receiving ticagrelor beyond 12 months and other off label use. |
Country | Name | City | State |
---|---|---|---|
China | Research Site | Baoding | |
China | Research Site | Beijing | |
China | Research Site | Changzhi | |
China | Research Site | Chongqing | |
China | Research Site | Guangzhou | |
China | Research Site | Guiyang | |
China | Research Site | Haerbin | |
China | Research Site | Hangzhou | |
China | Research Site | Hebei | |
China | Research Site | Jilin | |
China | Research Site | Jinan | |
China | Research Site | Jinzhong | |
China | Research Site | Kunming | |
China | Research Site | Lanzhou | |
China | Research Site | Nanjing | |
China | Research Site | Nanning | |
China | Research Site | Peking | |
China | Research Site | Shanghai | |
China | Research Site | Shenyang | |
China | Research Site | Shenzhen | |
China | Research Site | Shihezi | |
China | Research Site | Taiyuan | |
China | Research Site | Tangshan | |
China | Research Site | Tianjin | |
China | Research Site | Wuhan | |
China | Research Site | Wulumuqi | |
China | Research Site | Wuxi | |
China | Research Site | Xian | |
China | Research Site | Xining | |
China | Research Site | Xuzhou | |
China | Research Site | Yinchuan | |
China | Research Site | Yulin | |
China | Research Site | Zhengzhou | |
China | Research Site | Zhenjiang |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Long-term antithrombotic management patterns in a real-life setting by assessing the medication and treatment prescribed by physicians | From 2 years after the acute coronary syndrome index event, assessed up to 5 years | ||
Secondary | Clinical outcomes by record the number and type of cardiovascular and non-cardiovascular events | From 2 years after the acute coronary syndrome index event, assessed up to 5 years | ||
Secondary | Health care resource consumption and related costs by assessing the detail hospitalization and outpatient cost. | From 2 years after the acute coronary syndrome index event, assessed up to 5 years | ||
Secondary | Quality of life by assessing EQ-5D questionnaire. | 2 years,2.5years,3years,3.5years,4years,4.5years,5years after the acute coronary syndrome index event |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02552407 -
Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis
|
N/A | |
Completed |
NCT01398228 -
Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3,CPACS-3
|
N/A | |
Completed |
NCT01135667 -
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
|
Phase 4 | |
Recruiting |
NCT02592720 -
Cocktail Injection Improves Outcomes of FFR Guided PCI
|
Phase 4 | |
Completed |
NCT01641510 -
PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
|
Phase 3 | |
Completed |
NCT01743274 -
Does Optical Coherence Tomography Optimise Results of Stenting
|
N/A | |
Active, not recruiting |
NCT01433627 -
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
|
Phase 3 | |
Completed |
NCT01452282 -
Ankle-Brachial Index Estimating Cardiac Complications After Surgery
|
N/A | |
Recruiting |
NCT01418794 -
Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease
|
Phase 4 | |
Recruiting |
NCT01000701 -
Inflammation and Acute Coronary Syndromes
|
N/A | |
Terminated |
NCT01107899 -
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
|
Phase 1 | |
Completed |
NCT00494247 -
Endothelial Progenitor Cells-capture Stents in Acute Coronary Syndromes
|
Phase 4 | |
Terminated |
NCT00615719 -
Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation
|
N/A | |
Active, not recruiting |
NCT06089343 -
High-risk Features of Coronary Lesions in CTA and OCT
|
||
Not yet recruiting |
NCT04023630 -
DUAL Antithrombotic Therapy in Patients With AF and ACS
|
Phase 4 | |
Recruiting |
NCT02601404 -
REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)
|
N/A | |
Completed |
NCT02195193 -
Integrating Depression Care in Acute Coronary Syndromes Care in China
|
N/A | |
Completed |
NCT02141750 -
THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES
|
N/A | |
Not yet recruiting |
NCT01735227 -
Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)
|
Phase 4 | |
Completed |
NCT00097591 -
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
|
Phase 3 |